Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
Dr. José E. Igoa, a prominent figure in the field of psychiatry, has a rich and diverse background that reinforces his expertise.
DHR Health stands at the forefront of minimally invasive robotic surgery in South Texas, exemplified by its Institute of Robotic Surgery, which successfully completes over 1,000 robotic cases annually. With the recent inauguration of DHR Health Brownsville, this advanced expertise in Minimally Invasive Surgical procedures is extending its reach to the lower Rio Grande Valley. In a groundbreaking milestone last month, Dr. Rene Luna conducted DHR Health Brownsville's inaugural Robotic Surgery.